Trial Profile
The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms StatVax
- 24 Jan 2019 Primary endpoint (fold change in total anti-pneumococcal antibody titer between treatment groups.) has been met as per results published in the Vaccine
- 24 Jan 2019 Results published in the Vaccine
- 25 Sep 2015 Phase is changed fro 4 to 1 as reported by ClinicalTrials.gov record